Alector Inc Asset Resilience Ratio
Alector Inc asset resilience ratio. Alector Inc (ALEC) has an Asset Resilience Ratio of 64.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALEC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alector Inc (2018–2025)
Asset resilience ratio of Alector Inc from 2018 to 2025. This chart shows how Alector Inc's Asset Resilience Ratio has changed over time. Read Alector Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alector Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALEC current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $190.22 Million | 64.87% |
| Total Liquid Assets | $190.22 Million | 64.87% |
Asset Resilience Insights
- Very High Liquidity: Alector Inc maintains exceptional liquid asset reserves at 64.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alector Inc Industry Peers by Asset Resilience Ratio
Compare Alector Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Alector Inc Asset Resilience Ratio by Year (2018–2025)
Alector Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Alector Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.87% | $190.22 Million | $293.24 Million | -16.35pp |
| 2024-12-31 | 81.22% | $380.38 Million | $468.30 Million | +4.95pp |
| 2023-12-31 | 76.28% | $474.31 Million | $621.83 Million | +5.37pp |
| 2022-12-31 | 70.91% | $558.53 Million | $787.65 Million | +21.06pp |
| 2021-12-31 | 49.85% | $406.10 Million | $814.66 Million | -24.57pp |
| 2020-12-31 | 74.42% | $363.34 Million | $488.25 Million | +11.98pp |
| 2019-12-31 | 62.44% | $263.43 Million | $421.91 Million | -10.51pp |
| 2018-12-31 | 72.95% | $224.94 Million | $308.36 Million | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more